Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

THG 113

Drug Profile

THG 113

Alternative Names: PDC-31; PDC-41; PHG 113; THG113.31

Latest Information Update: 14 Mar 2016

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Theratechnologies
  • Developer PDC Biotech
  • Class Peptides
  • Mechanism of Action Prostaglandin F2 alpha antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Dysmenorrhoea; Preterm labour

Most Recent Events

  • 10 Dec 2012 PDC Biotech completes a phase I trial in Dysmenorrhoea in Austria and Germany (NCT01250587)
  • 24 Jan 2012 Phase-I development is ongoing in Austria and Germany
  • 12 May 2008 THG 113 licensed to PDC Biotech worldwide for the treatment of Dysmenorrhoea and prevention of Preterm labour
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top